Heptares

0:02:30

Introduction to Sosei Heptares

0:03:41

Sosei Heptares Approach to Drug Discovery

0:07:55

Virtual Tour of Sosei Heptares’s State-of-the-Art R&D Center

0:01:15

Sosei Heptares Japan 1 Investor Motion Graphic Explainer

0:03:24

GPCR and StaR® technology (English)

0:00:30

HEPTARES LIMITED EFFECTS VIT2

0:00:11

HEPTARES LIMITED / YTV/ NELVANA LIMITED/ NICKELODEON

0:25:32

New treatments being developed for schizophrenia

0:00:12

HEPTARES LIMITED/ YTV A CORUS ENTERTAINMENT INC / NELVANA LIMITED/ NICKELODEON

0:02:54

Malcolm Weir, CEO at Heptares with a Receptor Platform Worth Billions - 2016

0:02:02

LOGOS HEPTARES 1990-1993-1991-2012-2013-2014-2015-2016-2017-2019 LOGO COMPALITION

0:00:10

Televisa/Pé-de-Meia Animation /Nickelodeon/Heptares lnternational Limited/Nelvana Limited

0:02:25

G Protein Coupled Receptor

0:00:32

New Trial for Better Sleep: Nxera’s Daridorexant!

0:02:03

Introducing G-protein-coupled Receptors and Allosteric modulation

0:00:58

Takaki Shimura, Sosei Ltd. BME Research Laboratory, Japan

0:01:20

Sosei Reaches Deal With Neurocrine On Neuropsychiatric Disorders; Eligible To Receive Up To $2.6 Bln

0:00:41

Sosei Group (4565 JP) TSE Prime Promotion and TOPIX Inclusion... Finally

0:52:04

Allosterism in GPCRs

0:32:01

Ali Jazayeri | UK | Antibodies 2015| Conference Series LLC